Findings from a recent survey published last month in Frontiers in Rehabilitation Sciences on the effectiveness of Amicapsil, a micropore particle technology (MPPT), in treating pressure ulcers in individuals with spinal cord injuries showed a 100% success rate in chronic and acute wounds.
Researchers in Britain asked 41 volunteers with spinal cord injuries to apply Amicapsil, a white, odorless powder, to their pressure ulcers daily for four weeks. Unlike traditional treatments, this new product works by reducing moisture and inhibiting the growth of harmful bacteria and fungi in a pressure ulcer, allowing the body’s own immune system and healthy bacteria to promote wound healing.
People living with spinal cord injuries are at increased risk of developing pressure ulcers and are immunocompromised due to disrupted communication between the nervous and immune systems. As a result, pressure ulcers often worsen and lead to the development of osteomyelitis—a life-threatening infection that can require surgical intervention.
Pressure ulcers can take weeks, months or even years to heal, and may require professional help for treatment. Amicapsil treatments can be managed independently through telemedicine and do not require bedrest. The technology requires air to function, so wounds can be covered with light cotton gauze, or left uncovered. If air access is blocked by activities such as sitting, an air pump can be used to provide airflow.
Prior research indicates that Amicapsil can remove infections 60% quicker and accelerate skin regeneration by 50% compared to standard antimicrobial treatments, which use antibiotics and antiseptics. Additionally, it shortens the average in-hospital stay for wound treatment from one week to three to five days.
Overall, volunteers reported this treatment significantly improved their quality of life and independence. Further research is needed before this product becomes widely available.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Leave a Reply